Screener
Recursion Pharmaceuticals, Inc. RXRX Goodwill
Goodwill at other companies
Other financials
Where this comes from
Reported directly by Recursion Pharmaceuticals, Inc. in its filing.
Tagged under the XBRL concept us-gaap:Goodwill.
The source filing: Recursion Pharmaceuticals, Inc.’s 10-Q, filed August 5, 2026.
- Filed
- Aug 5, 2026, 6:32 AM EDT
- Fiscal quarter
- Q2 FY2026
- Calendar quarter
- Q2 2026
- Accession
- 0001601830-26-000098
| Line item | June 30, 2026 | December 31, 2025 |
|---|---|---|
| Operating lease right-of-use assets | 40,271 | 45,339 |
| Financing lease right-of-use assets | 17,179 | 20,210 |
| Intangible assets, net | 282,888 | 309,903 |
| Goodwill | 160,350 | 162,158 |
| Deferred tax assets | 957 | 957 |
| Other assets, non-current | 12,186 | 12,754 |
| Total assets | $1,212,668 | $1,474,130 |
| Liabilities and stockholders’ equity |
Item 1. Financial Statements (unaudited)
FAQ
- What is Recursion Pharmaceuticals, Inc.'s goodwill?
- Recursion Pharmaceuticals, Inc. (RXRX) reported goodwill of $160.35M in Q2 2026.
- How has Recursion Pharmaceuticals, Inc.'s goodwill changed year-over-year?
- Recursion Pharmaceuticals, Inc.'s goodwill decreased by 2.4% year-over-year, from $164.27M to $160.35M.
- What is the long-term trend for Recursion Pharmaceuticals, Inc.'s goodwill?
- Over 5 years (2020 to 2025), Recursion Pharmaceuticals, Inc.'s goodwill has grown at a 189.2% compound annual growth rate (CAGR), from $801K to $162.16M.
- What does goodwill mean?
- The excess of acquisition cost over the fair value of net identifiable assets acquired — representing brand value, customer relationships, and synergies from past M&A.
Ask your AI about Recursion Pharmaceuticals, Inc.'s goodwill.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude